Novel human CYP2A6 alleles confound gene deletion analysis

FEBS Letters

Volumn 569, Issue 1-3, 2004, Pages 75-81

  Nakajima, Miki ^a   Yoshida, Ryoko ^a   Fukami, Tatsuki ^a   McLeod, Howard L ^b   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coumarin 7 hydroxylation; Cytochrome P450; Genetic polymorphism; Interindividual difference; Nicotine metabolism

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 2A6;

AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; DNA SEQUENCE; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; INTRON; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; EXONS; GENE DELETION; GENETIC TECHNIQUES; GENOTYPE; HUMANS; INTRONS; MIXED FUNCTION OXYGENASES; OLIGODEOXYRIBONUCLEOTIDES; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 3042635940     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2004.05.053     Document Type: Article

References (29)

1. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab. Dispos. 29:2001;91-95
2. Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24:1996;1212-1217
3. ′ -hydroxylation of cotinine in human liver microsomes J. Pharmacol. Exp. Ther. 277:1996;1010-1015
4. Oscarson M., McLellan R.A., Gullstén H., Agúndez J.A.G., Benítez J., Rautio A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Identification and characterization of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett. 460:1999;321-327
5. Fernandez-Salguero P., Hoffman S.M.G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J.-D., Evans W.E., Idle J.R. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:1995;651-660
6. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329
7. Kitagawa K., Kunugita N., Kitagawa M., Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem. 276:2001;17830-17835
8. Ariyoshi N., Sawamura Y., Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem. Biophys. Res. Commun. 281:2001;810-814
9. Daigo S., Takahashi Y., Fujieda M., Ariyoshi N., Yamazaki H., Koizumi W., Tanabe S., Saigenji K., Nagayama S., Ikeda K., Nishioka Y., Kamataki T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 12:2002;299-306
10. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284:2001;455-460
11. Yoshida R., Nakajima M., Watanabe Y., Kwon J.-T., Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol. 54:2002;511-517
12. Xu C., Rao Y.S., Hoffmann E., Jones J., Sellers E.M., Tyndale R.F. An in vivo pilot study characterizing the new CYP2A6*7,*8, and*10 alleles. Biochem. Biophys. Res. Commun. 290:2002;318-324
13. Nunoya K., Yokoi T., Kimura K., Kainuma T., Satoh K., Kinoshita M., Kamataki T. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3, 5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther. 289:1999;437-442
14. Nunoya K., Yokoi T., Takahashi Y., Kimura K., Kinoshita M., Kamataki T. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of entire CYP2A6 gene associated with the poor metabolizer phenotype. J. Biochem. 126:1999;402-407
15. Oscarson M., McLellan R.A., Gullstén H., Yue Q.-Y., Lang M.A., Bernal M.L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448:1999;105-110
16. Ariyoshi N., Takahashi Y., Miyamoto M., Umetsu Y., Daigo S., Tateishi T., Kobayashi S., Mizorogi Y., Loriot M.-A., Stücker I., Beaune P., Kinoshita M., Kamataki T. Structural characterization of a new variant of theCYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics. 10:2000;687-693
17. Ariyoshi N., Sekine H., Saito K., Kamataki T. Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics. 12:2002;501-504
18. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E.M., Tyndale R.F. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58:2000;747-755
19. Oscarson M., McLellan R.A., Asp V., Ledesma M., Ruiz M.L.B., Sinues B., Rautio A., Ingelman-Sundberg M. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat. 20:2002;275-283
20. Kiyotani K., Fujieda M., Yamazaki H., Shimada T., Guengerich F.P., Parkinson A., Nakagawa K., Ishizaki T., Kamataki T. Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab. Pharmacokin. 17:2002;482-487
21. Nakajima M., Yamagishi S., Yamamoto H., Yamamoto T., Kuroiwa Y., Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin. Pharmacol. Ther. 67:2000;57-69
22. Nakajima M., Kwon J., Tanaka N., Zenta T., Yamamoto Y., Yamamoto H., Yamazaki H., Yamamoto T., Kuroiwa Y., Yokoi T. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther. 69:2001;72-78
23. Kwon J.-T., Nakajima M., Chai S., Yom Y.-K., Kim H.-K., Yamazaki H., Sohn D.-R., Yamamoto T., Kuroiwa Y., Yokoi T. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics. 11:2001;317-323
24. Yoshida R., Nakajima M., Watanabe Y., Kwon J.-T., Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol. 54:2002;511-517
25. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J.-T., Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of mRNA and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. 74:2003;69-96
26. Benowitz N.L, Griffin C., Tyndale R. Deficient C-oxidation of nicotine continued. Clin. Pharmacol. Ther. 70:2001;567
27. Nakajima M., Kuroiwa Y., Yokoi T. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab. Rev. 34:2002;865-877
28. Pianezza M.L., Sellers E.M., Tyndale R.F. Nicotine metabolism defect reduces smoking. Nature. 393:1998;750
29. Miyamoto M., Umetsu Y., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., Nemoto N., Sato K., Ariyoshi N., Kamataki T. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 261:1999;658-660